Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function.

TRAIL anti-myeloma activity caspase-8 cell viability cereblon cleavage lenalidomide multiple myeloma

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2020
Historique:
received: 14 09 2020
accepted: 20 11 2020
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 5 1 2021
Statut: epublish

Résumé

Cereblon (CRBN), a substrate receptor of cullin 4-RING E3 ligase (CRL4), mediates the ubiquitination and degradation of constitutive substrates and immunomodulatory drug-induced neo-substrates including MEIS2, c-Jun, CLC1, IKZF1/3, CK1α, and SALL4. It has been reported that CRBN itself could be degraded through the ubiquitin-proteasome system by its associated or other cullin-RING E3 ligases, thus influencing its biological functions. However, it is unknown whether the CRBN stability and its biological function could be modulated by caspases. In this study, using model cell lines, we found that activation of the death receptor using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) leads to the decreased CRBN protein level. Through pharmacological inhibition and activation of caspase-8 (CASP-8), we disclosed that CASP-8 regulates CRBN cleavage in cell lines. Site mapping experiments revealed that CRBN is cleaved after Asp9 upon CASP-8 activation, resulting in the reduced stability. Using myeloma as a model system, we further revealed that either inhibition or genetic depletion of CASP-8 enhances the anti-myeloma activity of lenalidomide (Len) by impairing CRBN cleavage, leading to the attenuated IKZF1 and IKZF3 protein levels and the reduced viability of myeloma cell lines and primary myeloma cells from patients. The present study discovered that the stability of the substrate receptor of an E3 ligase can be modulated by CASP-8 and suggested that administration of CASP-8 inhibitors enhances the overall effectiveness of Len-based combination therapy in myeloma.

Identifiants

pubmed: 33392195
doi: 10.3389/fcell.2020.605989
pmc: PMC7773819
doi:

Types de publication

Journal Article

Langues

eng

Pagination

605989

Subventions

Organisme : NCI NIH HHS
ID : R01 CA186702
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS111631
Pays : United States

Informations de copyright

Copyright © 2020 Zhou, Yu, Jayabalan, Niesvizky, Jaffrey, Huang and Xu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Apoptosis. 2003 Aug;8(4):337-43
pubmed: 12815276
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):443-449
pubmed: 30458989
Cell. 1999 Mar 5;96(5):615-24
pubmed: 10089877
Br J Haematol. 2014 Jan;164(2):233-44
pubmed: 24206017
Cell. 1998 Aug 21;94(4):481-90
pubmed: 9727491
PLoS Genet. 2018 Jan 25;14(1):e1007165
pubmed: 29370161
Blood. 2000 Oct 1;96(7):2528-36
pubmed: 11001907
Cell. 2006 Mar 24;124(6):1283-98
pubmed: 16564017
Blood. 2011 Nov 3;118(18):4771-9
pubmed: 21860026
Mol Cancer Ther. 2007 Jul;6(7):2103-12
pubmed: 17620439
Nature. 2006 Oct 5;443(7111):590-3
pubmed: 16964240
J Biol Chem. 2013 Oct 11;288(41):29573-85
pubmed: 23983124
Science. 2014 Jan 17;343(6168):305-9
pubmed: 24292623
Science. 2010 Mar 12;327(5971):1345-50
pubmed: 20223979
Nat Commun. 2017 May 22;8:15398
pubmed: 28530236
FASEB J. 2015 Dec;29(12):4829-39
pubmed: 26231201
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12432-7
pubmed: 22802652
Biochem J. 2000 Sep 1;350 Pt 2:563-8
pubmed: 10947972
Leukemia. 2012 Nov;26(11):2326-35
pubmed: 22552008
Blood. 2010 Jan 28;115(4):834-45
pubmed: 19965674
Adv Hematol. 2012;2012:842945
pubmed: 22919394
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Trends Biochem Sci. 2009 Nov;34(11):562-70
pubmed: 19818632
Leukemia. 2019 Jan;33(1):171-180
pubmed: 30026574
Blood. 2018 Sep 20;132(12):1293-1303
pubmed: 30042095
Elife. 2018 Aug 01;7:
pubmed: 30067223
Blood. 2012 Aug 2;120(5):1095-106
pubmed: 22718837
Cell Death Dis. 2019 Jan 25;10(2):69
pubmed: 30683842
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
BMC Cancer. 2016 May 03;16:297
pubmed: 27142104
Acta Pharmacol Sin. 2015 Nov;36(11):1300-7
pubmed: 26364802
Blood. 2002 Jun 15;99(12):4525-30
pubmed: 12036884
Br J Haematol. 2015 Dec;171(5):798-812
pubmed: 26456076
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Nat Chem Biol. 2018 Oct;14(10):981-987
pubmed: 30190590
Leukemia. 1999 Nov;13(11):1817-24
pubmed: 10557057
Leukemia. 2014 May;28(5):1129-31
pubmed: 24166296
Cell. 1998 Aug 21;94(4):491-501
pubmed: 9727492
Blood. 2003 Feb 15;101(4):1530-4
pubmed: 12393500

Auteurs

Liang Zhou (L)

Jiangsu Key Laboratory of Neuropsychiatric Diseases, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

Wenjun Yu (W)

Jiangsu Key Laboratory of Neuropsychiatric Diseases, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

David S Jayabalan (DS)

Department of Medicine, Weill Cornell Medicine, New York, NY, United States.

Ruben Niesvizky (R)

Department of Medicine, Weill Cornell Medicine, New York, NY, United States.

Samie R Jaffrey (SR)

Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States.

Xiangao Huang (X)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States.

Guoqiang Xu (G)

Jiangsu Key Laboratory of Neuropsychiatric Diseases, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

Classifications MeSH